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BACKGROUND. The incidence and prevalence of both benign prostatic hypertrophy (BPH)
and prostate cancer (PCa) increase with the aging process. Our laboratory recently showed that
the chemokines CXCL5 and CXCL12, which normally function as inflammatory mediators,
are secreted at higher levels by aging prostate stromal fibroblasts and elicit proliferative
responses from both prostate stromal fibroblast and epithelial cells. Because both CXCL5 and
CXCL12 are secretedmolecules, we hypothesized that their levels in patient serummight serve
as biomarkers to distinguish between BPH and PCa.
METHODS. Serum CXCL5 and CXCL12 levels were determined using sandwich ELISAs for
51 men demonstrating low serum PSA values of10 ng/ml who underwent diagnostic needle
biopsy for the detection of PCa. The bivariate relationship of circulating chemokine levels, age,
and disease status in the prostate was tested using the Wilcoxon rank-sum test.
RESULTS. Total serum CXCL12 levels were significantly higher for men who were biopsy
positive compared to those who were biopsy negative for cancer and histological prostatitis
(P¼ 0.050). Among men who were biopsy negative for PCa, total serum CXCL5 levels were
inversely associated with prostate volume and were significantly higher in men with
concomitant BPH and histological prostatitis compared to those without evidence of prostatic
disease (P< 0.003).
CONCLUSIONS. The results of this pilot and feasibility study suggest that serum or plasma
CXCL5 and CXCL12 levels may potentially distinguish between BPH and PCa among patients
presenting with low serum PSA, and may be useful toward facilitating decisions to perform
diagnostic needle biopsy in this patient population. Prostate 68: 442–452, 2008.
# 2008 Wiley-Liss, Inc.
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INTRODUCTION
Benign Prostatic Hypertrophy (BPH, also referred to
as benign prostatic enlargement) is one of the most
common benign proliferative conditions associated
with aging in men [1–3]. BPH is pathologically
characterized by cellular proliferation of the epithelial
and stromal elements primarily within the periure-
thral, or transitional zone, region of the prostate gland
[1–3,4]. In a survey of 1,709 men without cancer
reported by the Massachusetts Male Aging Study, the
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frequency of clinical BPH (defined in terms of
frequency/difficulty with urinating and evidence of
an enlarged/swollen prostate) rose from 8.4% in men
38–49 years of age to 33.5% in men aged 60–70 years
(P< 0.001) [2]. The incidence of BPH in associationwith
aging is much higher than the incidence of symptom-
inducing clinical BPH, for example, lower urinary tract
symptoms (LUTS) [5].However, LUTSmayprogress to
bladder outlet obstruction-related disorders, including
acute urinary retention (AUR) that may require
therapeutic and/or surgical intervention [6]. Aging is
also a risk factor in the development of prostatic
malignancies as theAmericanCancer Society estimates
that the probability of developing an invasive prostate
cancer (PCa) in 2007 is 0.01% between birth and the
fourth decade of life, but rises to 2.59% in the fifth
decade, 7.03% in the sixthdecade, 13.83% in the seventh
decade, and 17.12% in the eighth decade of life for
Americanmen [7]. Clearly, age is amajor risk factor for
the development of both BPH and PCa.
The biological mechanisms responsible for the
observed increase in age-associated risk for the devel-
opment of BPH and PCa are poorly understood. The
finding that chemokine-type inflammatory mediators
are secreted consequent to aging and promote prolif-
erative responses from both non-transformed and
transformed prostate epithelial cells suggests that
inflammation and inflammatory responses might play
a causal role in the development of both BPH and PCa
[8]. Indeed, the frequent observation of inflammatory
infiltrate in theprostate coincidentwithBPHorPCahas
provoked intense interest in the potential role of
inflammatory mediators in the etiology of both
diseases. For example, Nickel et al. described studies
that examined sectioned transurethral resection of the
prostate (TURP) specimens from 80 consecutive
patients with a diagnosis of BPH but no history or
symptoms of prostatitis. Inflammatory cells were
detected in 90% of specimens examined, regardless of
whether the patient had been catheterized for urinary
retention prior to TURP or whether bacterial growth
resulted fromcultured specimens. They concluded that
prostatic inflammation is an extremely common histo-
logical finding in patients with BPH who have no
symptoms of prostatitis, though the clinical signifi-
cance of asymptomatic chronic prostatitis associated
with BPH had yet to be determined [9]. In another
study, Gerstenbluth et al. identified pervasive chronic
prostatitis in whole mount radical prostatectomy
specimens from a series of 40 consecutive patients with
clinically localized PCa. Although inflammation was
associated with both BPH and cancer, it was observed
more frequently with BPH. They concluded that these
findings indirectly supported a potential role for
inflammation in the pathogenesis of BPH [10]. Data
recently reported by Roehrborn obtained from exam-
ining baseline prostate biopsies in a subgroup of 1197
randomly selected patients in the Medical Therapy of
Prostatic Symptoms (MTOPS) study demonstrated
chronic inflammatory infiltrate in 30–60% of men with
BPH. Patients with chronic inflammatory infiltrate had
larger prostate volumes and demonstrated signifi-
cantly more clinical progression and AUR than those
who had no inflammation [11,12].
With regard to the role of inflammation in prostate
tumorigenesis, DeMarzo et al. have identified a type of
hyperproliferative lesion in the prostate that is asso-
ciated with inflammation and is morphologically
similar to prostatic atrophy termed proliferative
inflammatory atrophy, or PIA [13]. This group also
showed that high-grade prostatic intraepithelial neo-
plasia (PIN) is often observed in proximity to PIA, and
that morphologic transitions between high-grade PIN
and PIA occur frequentlywithin the same acinus/duct.
These and other studies suggest a model in which
proliferative epithelium associated with inflammation
may progress to PIN and/or adenocarcinoma [13–15].
Epidemiological studies also have noted an increased
risk for PCa among men with a history of prostatic
inflammation [16]. Though only associative, these
studies are suggestive of a link between inflammatory
processes and prostate tumorigenesis.
Detection rates for PCa in men demonstrating total
serum PSA (tPSA) values greater than 10 ng/ml are
typically 70% or higher when combined with findings
of abnormal digital rectal exam (DRE) or with
histological evidence based on >6 needle biopsy
specimens [17,18]. These rates, however, are much
lower for men demonstrating tPSA values of <10 ng/
ml. For example, malignant glands were detected on
needle biopsy for 30% of men whose tPSA values
were between 4 and 10 ng/ml, and tumor detection fell
to 21–23% among men with detectable tPSA values of
<4 ng/ml [19–21]. This suggests that factors other than
cancer may contribute to the elevation in PSA in the
serum. Indeed, elevated serum tPSA values correlate
directly with histological evidence of inflammation on
needle biopsy in patients asymptomatic for prostatitis
[22]. Another study evaluating patients enrolled in the
Chronic Prostatitis Cohort Study and age-matched
controls found that total and other forms of serum PSA
was elevated in men diagnosed with chronic prostati-
tis/chronic pelvic pain syndrome. Importantly, this
study determined that total and other forms of serum
PSA alone did not demonstrate sufficient sensitivity
and specificity for use as diagnosticmarkers for chronic
prostatitis/chronic pelvic pain syndrome [23]. Lastly,
larger prostate volumemay contribute to elevated tPSA
values in the absence of cancer. A recent study showed
that a smaller prostate volume is the strongest predictor
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of cancer detection in men exhibiting tPSA levels in the
2.0–9.0 ng/ml range, suggesting that tPSA is less useful
for the prediction of cancer in men with concurrent
BPH [24]. Several studies have shown that serum tPSA
values increase concomitantly with patient age in
parallel with increased incidence of BPH [25–29].
Taken together, these studies show that additional
serum biomarkers would be very valuable to distin-
guish between prostatic diseases in men exhibiting
serum PSA values of <10 ng/ml. Studies recently
reported from our laboratory showed that aging
prostate stromal cells cultured in vitro secrete CXC-
type chemokines, which act as potent growth factors
that promote the proliferation of both non-transformed
and transformed prostatic epithelial cells. These stud-
ies potentially link stromally secreted chemokine-type
inflammatory mediators consequent to aging with
benign and malignant proliferative diseases of the
prostate [8,30]. Based on these findings,we conducted a
pilot and feasibility study to test the hypothesis that the
serum concentrations of specific CXC-type chemokines
may provide objective criteria to facilitate a differential




The patient population was drawn from men
referred to the University of Michigan Health System
(UMHS) with an indication for prostate biopsy, for
example, rising or elevated total PSA, abnormal DRE,
high-grade PIN (HGPIN), or atypical small acinar
proliferation (ASAP) on prior biopsy, positive family
history of PCa, andknownPCaonwatchfulwaiting.As
not all of thesemenwent on to have surgical treatment,
only thosewith radical prostatectomy at our center had
additional pathological annotation beyond the biopsy.
Patients presenting for a prostate biopsy were app-
roached to participate in an on-going prospective
Prostate Biopsy Clinical database/Tissue Bank study
that enables several studies with Institutional Review
Board approval, including the prostate biopsy referral
database, the Early Detection Research Network
(EDRN), and the study reported here. Over the
12-month period between August 2005 and September
2006, 133 patients consented to the collection and use of
clinical data and tissue (serum, urine, prostate tissue).
The final study population of 51 patients was selected
for those exhibiting pre-biopsy tPSA values of10 ng/
ml (determined using the Abbott AxSYM polyclonal-
monoclonal immunoassay (AbbottDiagnostics, Abbott
Park, IL)), that approximated the observed frequencies
of biopsy-verified PCa (36%) and histological prostati-
tis (26%) in the larger EDRN study population, and
that permitted examination of equivalent cases of high-
volume disease within both the biopsy-negative and -
positive cases.
Collection of Clinical Data
Clinical and demographic data were collected from
the electronicmedical record (UMHSCareweb) or hard
copy medical records for all subjects. This data
included patient age, date of biopsy, physician, serum
PSA levels, medical history, comorbid conditions,
medications, physical examination including DRE
findings, prior history of prostate biopsies, cost related
to the procedure, complications, (AUA Symptom
Score/satisfaction with voiding situation), prostate
size based on the transrectal ultrasound (TRUS), and
findings from the prostate biopsies. Also, as patients
were seen in follow-up, any changes in disease status
or additional diagnostic testing were added to the
database.
Prostate volume data were gathered during a
standard TRUS examination performed using a
7.5 MHz biplanar endorectal probe. In addition to
assessing the echogenic pattern of the prostate gland,
three measurements were made to calculate total
prostatic volume. The anterior–posterior (AP) and
transverse (TR) diameters were measured at their
respective maximal dimensions, whereas the supe-
rior–inferior (SI) diameter was measured as the maxi-
mal length from the base to the apex of the prostate in
the midline sagittal plane. Total prostate volume was
estimated by static images using the formula for a
prolate ellipsoid, volume¼ p/6(TRAP SI).
LUTS severity information was gathered using the
American Urological Association Symptom Index
(AUASI) indices. These are generated from data
acquired from a patient-administered questionnaire,
the eight item validated American Urological Associ-
ation Symptom Score, which assesses the severity of
lower urinary symptoms in men that are most often
attributed to prostate disease. This survey is self-
completed by the patient prior to the prostate biopsy.
AUASI scores of 1–7 indicate none/mild LUTS, 8–19
indicate moderate LUTS, and 20–35 indicate severe
LUTS [31].
Collection of Clinical Specimens
Serum samples were collected just prior to prostate
needle biopsy in order to obviate anypotential surgical-
or trauma-induced impact on circulating chemokine or
other protein levels in this patient group. As standard
procedure, all patients were advised to refrain from
taking oral non-steroidal anti-inflammatory drugs
(NSAIDs) and other over-the-counter medications for
The Prostate
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1 week prior to biopsy. This served to minimize or
obviate potential medication-mediated fluctuations in
serum chemokine levels. For all patients, blood was
drawn into two 30cc heparinized tubes and one 15cc
EDTA tube, which were placed on ice and processed
within 12 hr. The blood in the heparinized tubes was
transferred into 15 ml tubes, centrifuged at 2,500 rpm
for 10 min, and stored in 200 ul aliquots in 0.5 ml
cryovials (Sarstedt) at808C.Theblood from theEDTA
tube was diluted with an equal volume of PBS and
subjected to Ficoll Hypaque density gradient centrifu-
gation to separate the lymphocyte granulocyte layer
(‘‘buffy coat’’) and plasma. The plasma layer was
carefully removed to a 15 ml tube and centrifuged at
4,000 rpm for 10 min at 48C to remove platelets and all
cellular contaminants. The platelet-free plasma was
stored at 808C in 200 ul aliquots in 0.5 ml cryovials
(Sarstedt).
Prostate biopsies were typically performed trans-
rectally using a 12-core extended biopsy template with
traditional paramedian sextant biopsies plus addi-
tional needle cores directed more laterally [32]. All
needle biopsies containing malignant glands were
quantitated as to percent of malignant tissue, and
further evaluation of perineural invasion or extrapro-
static extension was provided. All needle biopsies are
evaluated for the presence of HGPIN/ASAP, inflam-
mation (acute and chronic), hyperplasia, or other
histopathologies. When PCa was identified, each set
of needle biopsies was given an overall Gleason grade
based on the evaluation of the entire tumor.
Def|nitions of Prostatic Disease
Status and StudyGroups
These data are summarized in Table I. Disease status
was carefully defined in the study group, as delineated
below. It should be noted that some patients included
in the study were characterized by more than one
disease status.
No Disease. Criteria: No finding of cancer on prostate
biopsy. Negative diagnosis for histological prostatitis
based on negative findings for acute and/or chronic
inflammatory infiltrate on prostate biopsy or history
of clinically diagnosed prostatitis. Prostate volume
37.5 gonTRUS. Prostate biopsy specimens evaluated as
normal benign. PSA values 10 ng/ml. This com-
prised 13/51 (25%) of the total patient population
examined in this study.
Histological Prostatitis. Criteria: Histological diagno-
sis of acute and/or chronic inflammatory infiltrate for
oneormoreprostate biopsy specimens. This comprised
16/51 (31%) of the total patient population examined in
this study. Fifteen of these patients were biopsy
negative for cancer, and one was biopsy positive. NB:
none of the 51 patients in the patient population
examined in these studiesdescribed a clinical diagnosis
for prostatitis.
BPH. Criteria: Evidence for enlarged prostate. The
median prostate volume for the 51 patients included in
this study was 37.5 g. Therefore, this value was used to
define prostates as low volume (37.5 g) or high
volume (>37.5 g), roughly equivalent to measures
described as high volume and consistent with BPH in
the literature [24]. Men with BPH comprised 25/51
(49%) of the total patient population examined in this
study, 17/37 (46%) of biopsy-negative patients, and
8/14 (57%) of biopsy-positive patients. Although the
AUASI was recorded for all patients, it was not used to
define BPH.
Cancer. Criteria: Histological diagnosis of malignant
glands from prostate biopsy. This comprised 14/51
(27%) of the patient population examined in this study,
which approximated the proportion of patients (1/3,
33%) with biopsy-verified cancer within the larger
patient population comprising the EDRN study.
Five board-certified pathologists were involved in
the histologic diagnoses of the prostate biopsies. The
number of positive biopsies among these 14 patients
varied from 1 to 7, with a mean (and median) of two
positive biopsies per patient,with amean (andmedian)
Gleason score of 6. The subsequent treatment courses
for these patients varied widely, with five patients
undergoing laparoscopic or radical retropubic prosta-
tectomy, three patients undergoing external beam
radiation or brachytheraphy, four patients under
watchful waiting, and two patients who did not return
for treatment to the University of Michigan.
ELISAAssays
Circulating serum CXCL5 (ENA-78) or CXCL12
(SDF-1) chemokine levels were assessed using 50 ul
frozen serum or plasma per direct sandwich ELISA in
duplicate using the Human CXCL5/ENA-78 DuoSet
kit DY254 or theHumanCXCL12/SDF-1 alpha capture
antibody MAB350, detection antibody BAF310, and
standard 350-NS ELISA reagents (R&D Systems).
Measures within each patient group were regarded as
biological replicates and permitted statistical compar-
isons between groups. For all ELISAs, a standard curve
was generated with the provided standards and
utilized to calculate the quantity of chemokine in the
sample tested. These assays provide measures of
chemokines concentration with excellent reproducibil-
ity, with replicate measures characterized by standard
The Prostate
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deviations from the mean on the order of 1–2%.
Measures for each chemokine were performed for
all samples simultaneously to avoid potential ‘‘batch
effect’’ variations in measurement.
Statistical Analysis
The bivariate relationship of circulating chemokine
levels, age, and disease severity (gland volume, base-
line PSA, and AUASI) with disease status was tested in
this small patient population using theWilcoxon rank-
sum test. Separate tests were performed for each
definition of disease status (e.g., cancer vs. no cancer,
low volume vs. high volume, etc) in pairwise fashion.
Sample size prevented the ability to adjust for other
factors in a multivariable analysis or to construct
reliable receiver operator curve (ROC) analyses. All
tests were performed using SAS v9.1.3 at the 5%
significance level.
RESULTS
Clinico-Pathologic Characteristics of the
Patient Population
The study population of 51 patients was selected
for those cases exhibiting pre-biopsy tPSA values of
10 ng/ml, that roughly mirrored the observed
frequencies of biopsy-verified PCa (36%) and histolog-
ical prostatitis (26%) in the larger EDRN study
population, and would permit examination of equiv-
alent cases of high-volume disease (BPH) within both
the biopsy-negative and -positive cases. Although all
of the patients included in this study exhibited pre-
biopsy tPSA values of 10 ng/ml, these values were
significantly higher for men with BPH compared to
thosewithsmallerprostates (P< 0.001). Prostatevolume
itself varied concordantly with biopsy-diagnosed
histological prostatitis (acute, chronic, or both) such
that prostates without evidence of histological prosta-
titis were significantly smaller, with a median volume
of 34.4 g, than prostates with evidence of histological
prostatitis, with a median volume of 53.1 g (P¼ 0.008).
Men with evidence of histological prostatitis on needle
biopsy were significantly younger than those without
evidence of histological prostatitis, with a median age
of 54.0 compared to 61.0 years, respectively (P¼ 0.003).
This relationship held both in the presence (P¼ 0.021)
or absence (P¼ 0.039) of concurrent prostatic enlarge-
ment. Men that were biopsy positive for cancer
were older (median age 61.5 years) than men that
were biopsy-negative cancer for cancer (median age
57.0 years) but this difference was not significant
(P¼ 0.061). Results from completion of the AUASI
questionnaire for men without cancer demonstrated
similar scores consistent with moderate symptoms for
patients with smaller volume prostates (median score
8.5) or with prostatic enlargement (median score 9.0)
(P¼ 0.557). However, men with cancer reported sig-
nificantly higher scores consistent with moderate
symptoms (median score 11.5) concordant with pro-
static enlargement compared to men with smaller
prostates who reported scores consistent with none or
mild symptoms (median score 4.0) (P¼ 0.003). The
presence or absence of biopsy-diagnosed histological
prostatitis was not associated with significant differ-
ences inAUASI scores among the patient population as
a whole or among men with or without cancer and/or
prostatic enlargement in particular. These data are
summarized in Table I.
SerumCXCL5 andCXCL12 Levels are Concordant
With the Presence of Prostatic Disease
Because CXCL5 and CXCL12 are secretedmolecules
and were found to be associated with aging and
prostate cellular proliferation, we hypothesized that
their levels in patient serum might, singly or in
combination, serve as biomarkers to distinguish
between BPH and PCa. To test this, ELISAs for CXCL5
and CXCL12 were performed on whole serum from 51
men enrolled in the EDRN study as described above.
The ELISA analyses showed that total serum CXCL12
levels were significantly higher for patients exhibiting
biopsy-verified cancer compared to men with who
were biopsy negative for cancer and histological
prostatitis (P¼ 0.050) (Table II and Fig. 1A). When
evaluated according to prostate volume, serum
CXCL12 levels were found to be lowest among men
without BPH, cancer, or histological evidence of
prostatitis. Moreover, serum CXCL12 levels were
significantly different between men with no evidence
of prostatic disease and men with biopsy-verified
cancer (P¼ 0.047) (Table II and Fig. 1C). Thus, serum
CXCL12 clearly distinguished men without prostatic
disease from those with cancer, and this predictive
value was most significant among men without BPH.
When analyzed without regard to prostate volume,
total serum CXCL5 levels were unable to definitively
distinguish between men with or without biopsy-
diagnosed cancer (Table II and Fig. 1B). However, total
serum CXCL5 levels were clearly inversely associated
with prostate volume, with median values almost
threefold higher in men with low volume prostates
compared to men with BPH but no other evidence of
prostatic disease (Table II and Fig. 1C). Among men
with BPH who were biopsy negative for cancer, total
serum CXCL5 levels were significantly higher in men
with concomitant histological prostatitis compared to
those without other evidence of disease (P< 0.003)
(Table II and Fig. 1C). Thus, serum CXCL5 levels were
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progressively elevated in, and predictive for, histolo-
gical prostatitis and PCa concurrent with BPH.
Comparison of ChemokineMeasurements
in Serumor Plasma
Because CXCR4 (the receptor for CXCL12) is
expressed on platelets, and CXCL5 can be released
from activated platelets, the CXCL12 andCXCL5 levels
were measured by ELISA (as described above) and
compared in both serum and platelet-free plasma from
6of the 51patients examined in this study. These assays
showed that ELISA-derived values for CXCL12 were
almost an order of magnitude lower, but parallel, in
serum compared to plasma samples from the same
patients (Fig. 1D). With the exception of values for one
patient (patient ‘‘B’’ in Fig. 1D), ELISA-derived values
forCXCL5were in good agreement between serumand
plasma samples from the same patients. For both
CXCL5 and CXCL12, however, the majority of ELISA-
derived values were higher in plasma compared to
serum samples, suggesting that plasma may provide a
more sensitive means for the quantitation of these
chemokines than serum.
DISCUSSION
The intent of the pilot and feasibility study reported
here was to determine whether the serum levels of
particular chemokine-type proteins secreted by aging
prostate stroma may be predictive for either benign or
malignant prostatic disease. The results of these studies
showed that serum CXCL12 levels were significantly
higher for patients exhibiting biopsy-verified cancer
compared to men with who were biopsy negative
for cancer and histological prostatitis. They also
showed that serum CXCL5 levels were progressively
elevated in men with histological prostatitis and PCa
concurrentwithBPH.Thus, serum levels ofCXCL5 and
CXCL12 differentially distinguished between BPH,
histological prostatitis, and PCa in the small patient
population examined in these studies.
These results are largely consistent with other
studies in the literature suggesting that the secretion
of particular cytokines and chemokines may be
associated with benign and malignant proliferative
disease. For example, Veltri et al. showed that serum
levels of the chemokine IL-8 (CXCL8) provided an
adjunct to serum PSA to distinguish between prostatic
diseases [33]. Androgen-responsive LNCaP and
LAPC-4 cells forced to over-express IL-8 exhibited
reduced dependence on androgen for growth,
decreased sensitivity to the anti-androgen, bicaluta-
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as well as increased tumor growth and microvessel
density in vivo compared to vector-transfected controls
[34]. Another recent study showed that androgen-
insensitive DU145 and PC3 cells exposed to exogenous
IL-8 demonstrated a rapid, time-dependent increase in
cyclin D1 expression concordant with cellular prolifer-
ation [35]. Taken together, these studies suggested that
IL-8 promotes androgen-independent PCa growth and
progression, and may serve as a marker to distinguish
between benign and malignant proliferative disease in
the prostate.
Other reports have clearly identified the chemokine
CXCL12 as a paracrine factor secreted by carcinoma-
associated fibroblasts (CAFs). Allinen et al. demon-
strated that CXCL12 was expressed and secreted at
higher levels by invasive ductal breast carcinoma-
associated stromal fibroblasts compared to normal-
associated stromal fibroblasts (NAFs), and could
promote the proliferation of cultured breast cancer
epithelial cells [36]. Orimo et al. showed that CAFs
extracted from invasive human breast carcinomas are
more competent than non-transformed fibroblasts in
enhancing tumor growth of breast cancer cells,
and secrete increased levels of CXCL12 which both
recruits endothelial progenitor cells into a tumor mass,
thereby boosting tumor angiogenesis and enhances
The Prostate
Fig. 1. A:LogserumCXCL5orCXCL12(ng/ml)differsdependingonprostatediseasestatus.ELISA-derivedvaluesforserumCXCL12formen
withoutevidenceofprostaticdisease(white triangles),menwithoutcancerbutwithhistologicalprostatitis (gray triangles)andmenwithpros-
tatecancer(blacktriangles),aswellasthelogserumCXCL5formenwithoutevidenceofprostaticdisease(whitediamonds),menwithoutcancer
butwithhistological prostatitis (graydiamonds), andmenwithprostate cancer (blackdiamonds) are shownon a logarithmic scale. Significant
differences (P< 0.050) are indicatedby *, trends (0.065< P< 0.050) by#.B: Log serumCXCL5 (ng/ml) relevant to prostate volume.ELISA-
derivedvalues for serumCXCL5 formenwith low volume (37.5 g) (circles) or high-volume (>37.5 g) (diamonds) prostateswithoutcanceror
histological prostatitis (white), withoutcancer butwithhistological prostatitis (gray), or with cancer (black) are shown on a logarithmic scale
Differencesbetweengroups thatachievedstatisticalsignificance(P< 0.05)areindicatedby*;trendsby#.Thedatarepresentedherearedrawn
fromTable II.C: Log serum CXCL12 (ng/ml) relevant to prostate volume. ELISA-derived values for serum CXCL12 formenwith low volume
(37.5 g) (circles) or high-volume (>37.5 g) (diamonds) prostates without cancer or histological prostatitis (white), without cancer but with
histological prostatitis (gray), or with cancer (black) are shown on a logarithmic scale.Differences between groups that achieved statistical
significance (P< 0.05) is indicatedby *; trends by#.The data representedhere is drawn fromTable II.D: Log chemokine values in serum and
plasma.ELISA-derivedvalues forCXCL12 (left) orCXCL5 (right) from serum (diamonds) orplasma (squares) are shownon a logarithmic scale
for6of the51patientsexaminedin this study.
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tumor growth by direct paracrine stimulation via the
CXCR4 receptor [37]. Studies utilizing co-cultured non-
transformed human prostate-derived fibroblasts and
the LNCaP PCa cell line clearly demonstrated that
epithelial–stromal paracrine interactions enhanced the
ability of xenografted LNCaP cells to grow as tumors in
athymic mice [38]. Further work showed that prostatic
CAFs stimulated tumor progression of immortalized
non-tumorigenic epithelial cells both in vitro and in
vivo [39]. Many studies have shown that chemokine–
chemokine receptor interactions, particularly those
between CXCL12 and CXCR4, stimulate chemotaxis
in vitro and promotemetastasis in vivo in prostate [40–
43] breast [44–49] and lung [50] cancers. Taken
together, these studies show that CXCR4/CXCL12-
mediated signaling is involved in breast, small cell
lung, and PCa cell proliferation and acquisition of an
invasive phenotype in vitro and in vivo. Our finding,
that serum CXCL12 levels are elevated in men with
PCa, is consistent with these studies andwith a role for
this paracrine factor in prostate tumorigenesis.
A concern with the patient population utilized in
these studies was that the presence of histological
prostatic inflammation might confound the interpreta-
tion of data based on the measurement of serum
chemokines, which are inflammatory mediators.
Although none of the patients enrolled in this study
complained of symptoms consistent with prostatitis or
had sought medical treatment for prostatitis, almost
one-third (16/51) of the study population exhibited
histological evidence of acute (9/16, 56%), both acute
and chronic (3/16, 19%), or chronic (4/16, 25%)
inflammation in one or more needle biopsy specimens.
Serum CXCL5 levels were progressively elevated in
men with BPH concurrent with histological prostatitis
(P¼ 0.003) or cancer (P¼ 0.061) compared to men
without prostatic disease, though serum CXCL12
levels were unaffected by the presence or absence of
histological prostatitis in the same patients. It is
unclear, however, whether evidence of histological
prostatitis, and, consequently, serum chemokine levels
relative to histological prostatitis, are clinically rele-
vant. Several studies have noted that prostatic inflam-
mation is an extremely common histological finding in
patients with BPH and/or cancer [9–12]. Hochreiter
et al. also reported that the levels of two chemokines,
IL-8 and CXCL5, were frequently elevated in the
expressed prostatic secretions from men diagnosed
with bacterial prostatitis, inflammatory chronic pelvic
pain syndrome, and asymptomatic inflammatory
prostatitis compared to normal controls. Theyhypothe-
sized that, because these cytokines are direct mediators
of leukocyte accumulation and activation at inflamma-
tory sites, they may be responsible, in part, for the
presence of inflammatory reactions in the prostate [51].
Taken together, these studies suggest a positive
association between histological prostatitis or clinically
significant prostatic inflammation and elevated serum
or prostatic CXCL5 levels. They also suggest a potential
association between prostatic inflammation and
enlargement. Our findings, that serum CXCL5 levels
were progressively elevated in men with BPH con-
current with histological prostatitis (P¼ 0.003) or
cancer (P¼ 0.061) compared to men without prostatic
disease, is an intriguing addition to the growing
literature associating inflammation with BPH and
cancer. They also point to the need to develop
experimentalmodels that provide themeans to directly
test the role of inflammation in the development of
benign prostatic proliferative disease.
CONCLUSIONS
Though preliminary, the results of the pilot and
feasibility study reported here suggest that CXCL12
may provide a serum or plasma biomarker for the
detection of PCa among men without BPH, while
CXCL5 may provide the same among men with BPH.
The use of such serumor plasmamarkers as adjuncts to
serum PSA may facilitate decisions to perform diag-
nostic needle biopsy in the increasingly large patient
population referred to Urology clinics who exhibit
detectable serum PSA values of <10 ng/ml. Though
dictated by the actual number of patient samples
available at the time of study initiation, a clearly
limiting factor of the study presented here is the
relatively small sample size examined. Due to this
limitation, these study results should be interpreted
with caution pending their validation in a larger study
population and, most importantly in a larger, multi-
institutional study to thoroughly test the efficacy of
these or other chemokines as serum or plasma
biomarker adjuncts to serum PSA for the indication of
diagnostic needle biopsy for the detection of PCa.
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